CClinicalTrials.gg
Sign In
Not yet recruitingNCT07793955Updated Sep 8, 2026

Intravenous Magnesium Sulphate Versus Lignocaine for Attenuating Hemodynamic Responses to Laryngoscopy and Endotracheal Intubation

An interventional study of Magnesium Sulphate infusion in Hemodynamic Response to Laryngoscopy and Tracheal Intubation, sponsored by Lady Reading Hospital, Pakistan. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Lady Reading Hospital, Pakistan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will compare intravenous magnesium sulfate with intravenous lidocaine for reducing the cardiovascular response to endotracheal intubation in adult patients undergoing general anesthesia. Eligible participants will receive either magnesium sulfate or lidocaine before endotracheal intubation. Heart rate and blood pressure will be recorded at predefined time points before and after intubation to compare the effectiveness of the two interventions in attenuating the hemodynamic response to laryngoscopy and endotracheal intubation.

02

Conditions studied

  • Hemodynamic Response to Laryngoscopy and Tracheal Intubation

Keywords

  • magnesium suplhate
  • lignocaine
  • endotracheal intubation
  • hemodynamic response
  • laryngoscopy
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age 18-70 yrs
  • male and female patients
  • patients undergoing elective or emergency procedures under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • anticipated difficult airway
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    intravenous Magnesiumm sulphate

    participants will receive intravenous magnesium Sulphate 30mg/kg diluted in 100ml normal saline ,administered 90 seconds before induction of general anesthesia

    Drug: Magnesium Sulphate infusion

  • Active comparator
    intravenous lignocaine

    participants will receive intravenous lignocaine 2mg/kg ,administered 90 seconds before induction of general anesthesia

    Drug: Magnesium Sulphate infusion

Interventions

  • DrugMagnesium Sulphate infusion

    intravenous magnesium Sulphate 30mg /kg diluted in 100ml normal saline, administered 90 sec before induction of general anesthesia

05

What researchers measure

Primary outcomes

  1. heart rate 5minutes after endotracheal intubation

    Time frame: 5 minutes after endotracheal intubation

  2. systolic blood pressure 5 minutes after endo tracheal intubation

    Time frame: 5 minutes after endotracheal intubation

  3. mean arterial pressure 5 minutes after endotracheal intubation

    Time frame: 5 minutes after endotracheal intubation

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07793955
Lead sponsor
Lady Reading Hospital, Pakistan
Responsible party
Syed Muhtaram Shah (Training Medical Officer, Department of Anesthesiology, Lady Reading Hospital, Pakistan) — Principal investigator
First posted
Aug 31, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Sep 20, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Lady Reading Hospital, Pakistan

Start the discussion